Binding Site Receives a Queen’s Award for Enterprise
News Apr 22, 2016
Binding Site has announced that it has been awarded a Queen’s award for enterprise - the UK’s highest accolade for business success. The honour has been awarded in the category of ‘International Trade’. For over 30 years Binding Site has specialised in producing highly sensitive and specific antibodies for the detection of certain cancers and other serious disorders which are delivered as in-vitro diagnostic test kits to hospitals and clinical laboratories globally.
Now the world leader in this area of clinical testing, Binding Site exports approximately 90% of the products manufactured at its Birmingham head office and has seen its international trade more than double in value from 2010 to 2015, with total worldwide Group revenues last year exceeding £80million.
“I am very proud to be able to announce this award as it recognises not only the combined efforts of all our staff and partners here and overseas, but also demonstrates the very real value of our products that is seen by physicians using them daily around the globe.” Charles de Rohan, CEO.
Employing over 700 people, 500 of whom are in the UK, the company continues to develop new products for the markets it serves, keeping in its sights the ultimate beneficiary – the patient. It wins the Queen’s Award for International Trade for continuous growth in overseas earnings of 103% over the last six years.
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE